Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

VJVirtual | COM503: the next steps in harnessing cytokines to treat cancer

Eran Ophir, PhD, Compugen Ltd., Tel Aviv, Israel, discusses future research directions for COM503, a potential first-in-class, high affinity anti- IL18 binding protein antibody with a novel approach to harnessing cytokine biology to treat cancer, including identifying suitable indications and biomarkers for this therapy. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.